- Home
- CBK vs ZURA Comparison
CBK vs ZURA Comparison
Compare CBK & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBK | ZURA |
|---|---|---|
| Founded | 1975 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.9M | 252.9M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | CBK | ZURA |
|---|---|---|
| Price | $24.38 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 127.2K | ★ 467.0K |
| Earning Date | 02-05-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.56 | N/A |
| EPS | ★ 2.67 | N/A |
| Revenue | ★ $89,675,266.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | ★ 14.31 | N/A |
| 52 Week Low | $23.36 | $0.97 |
| 52 Week High | $25.89 | $5.07 |
Technical Indicators
Market Signals| Indicator | CBK | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 76.58 |
| Support Level | N/A | $4.00 |
| Resistance Level | N/A | $4.44 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 0.00 | 95.97 |
Price Performance
Historical ComparisonAbout CBK Commercial Bancgroup Inc.
Commercial Bancgroup Inc a bank holding company. Through its subsidiary it is a full-service community banking institution that offers traditional consumer and commercial products and services to serve businesses and individuals in select markets in Kentucky, North Carolina, and Tennessee. Its service areas in Tennessee are (i) the Nashville MSA, (ii) the Knoxville MSA, and (iii) the Tri-Cities MSA, and (iv) Claiborne County, Cocke County, Union County, and Hamblen County, and their surrounding areas.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.